Seeking Alpha

GrowthGeek

GrowthGeek
Send Message
View as an RSS Feed
View GrowthGeek's Comments BY TICKER:
Latest  |  Highest rated
  • NQ Mobile Could Be The Latest Company To Be Acquired Or Taken Private: But At What Price? [View article]
    The short covering due to fears of delisting card has already been played as a reason that the share price went up after PwC was dismissed. Nice try though Mr short. Frankly, I'm surprised that the share price ended up today as well. Some think it might have been a "clearing of the deck" so to speak to clear the way for a buy out. I do see that as a more logical possibility than "a fear of delisting." I just don't really know so all of us are speculating.
    Aug 15 08:05 PM | 1 Like Like |Link to Comment
  • Has Gilead Priced Sovaldi Too High? [View article]
    Hep, most people here just fundamentally disagree with you. Most think that Sovaldi, even at its current price, is a godsend to those who suffer from HepC as it offers a cure in over 90% of cases (potentially better than that soon with a combination treatment) and it has much lower side effects than other treatments. Your continued ranting about GILD "raping" HepC sufferers and/or holding them hostage just isn't gaining traction.
    Even Wyden and Grassley in their objections to the current pricing are likely looking for a price reduction of something like 20% in reality (even if they quote a much bigger reduction). In any case, their asked for price is light years away from your $10 a pill demands.
    The only thing which seems to be "quietly creeping" into me due to most of your comments is indigestion. Perhaps you would be better served by posting on a political site. All you seem to do here is alienate and tick off people. I don't see how that serves your mission.
    Aug 15 07:30 PM | 3 Likes Like |Link to Comment
  • NQ Mobile Could Be The Latest Company To Be Acquired Or Taken Private: But At What Price? [View article]
    The grapevine states that QTR did not write an article today on the latest NQ drama "due to family reasons."
    I remain long NQ, but it helps to have a sense of humor when following this company : )
    Aug 15 07:13 PM | 3 Likes Like |Link to Comment
  • Regado Biosciences' Revolixys Kit: Assessing The Risks Of Allergic Reactions [View article]
    I concur with your assessment CTI. The risk vs. the reward equation of the REG-1 treatment as opposed to the available treatments certainly seems to come out in favor of REG-1 and this is likely why the "kit" was fast tracked by the FDA. My gut tells me that the FDA truly wants this treatment to reach the market, but has to be quite cautious in that optimism so as not to miss important safety concerns (hence the current halt). I know that the FDA tends to be very conservative when it comes to potential safety issues; I just hope that conservatism doesn't mean that they would throw out a very beneficial treatment which would save lives due, basically, to a technicality. I don't think that will happen. I trust that the FDA works better than that decision would indicate.
    If others can add insights to this discussion I would certainly welcome your thoughts.
    Aug 15 07:07 PM | Likes Like |Link to Comment
  • Regado Biosciences' Revolixys Kit: Assessing The Risks Of Allergic Reactions [View article]
    Good points Milberg and that's exactly what I have done to this point--continued to hold what I had invested when the share price dropped dramatically. I have been sorely tempted to add more shares at this blue light special price range, but, unless one of my other high risk high reward companies comes through with a big win, I am just holding tight for now.
    My best educated guess is that RGDO is easily over $4.50 by the end of October, but it remains a stock only for those comfortable with a good deal of risk. Before trial halt, funding/cash burn was seen as the major headwind regarding the share price and that concern remains.
    Aug 15 06:55 PM | 1 Like Like |Link to Comment
  • ClearSign Of Upside Potential [View article]
    Let us know when WSJ identifies CLIR as a fraud. Until then why don't you join the CYNK thread.
    Aug 15 06:39 PM | Likes Like |Link to Comment
  • NQ Mobile Could Be The Latest Company To Be Acquired Or Taken Private: But At What Price? [View article]
    With CFO resignation, is a buy out now more likely? Crazy swing in the share price today seems to indicate that many seem to think so. What started off as seemingly bad news now seems to be seen as good news by the market. It's easy to suffer whiplash when one follows NQ.
    Aug 15 02:18 PM | Likes Like |Link to Comment
  • Regado Biosciences' Revolixys Kit: Assessing The Risks Of Allergic Reactions [View article]
    Yes, thank you CTI and I apologize if my comment came off as critical as I did not mean it in that way.

    I do have one point of clarification that you might be able to shed some light on as I haven't read much discussion on this issue after the pause and the halt. It has always seemed to me that the Reg-1 kit two drug combo seems to have some crucial safety and efficacy benefits over the current treatment options with the anti-clotting dial down component. How do you think this gets factored in by the DSMB and/or the FDA? I would think that this would be a crucial factor in favor of Reg-1 even if allergic reactions are a problem for a small percentage of patients. Bleeding complications, including death, are certainly awful side effects of the current options.
    Aug 15 02:04 PM | Likes Like |Link to Comment
  • Regado Biosciences' Revolixys Kit: Assessing The Risks Of Allergic Reactions [View article]
    Thank you for exploring the science of allergic reactions in terms of what we know and can speculate about the Reg-1 kit. I didn't garner a lot of new information as I've been following this story closely as I remain long.
    Basically, RGDO presents an attractive risk reward for the more speculative investor as the trial will quite likely recommence, probably with some new exclusions to participation in the trial.
    Aug 15 11:52 AM | Likes Like |Link to Comment
  • Gilead Sciences Looks Like A Contrarian Short [View article]
    Um, it's actually been going up in recent days and weeks even when other biotech is going down.
    Aug 13 08:02 PM | 3 Likes Like |Link to Comment
  • ClearSign Of Upside Potential [View article]
    And it's sheer luck that you just happened to show up on a CLIR article comment thread to spread your bile after complaining that I hijacked a CVA article with one comment and a clarification after news. Dog, nice that you attack basically every individual on the thread with baseless false accusations. You are a true joy to know.
    Personally, I am not enamored with CLIR management at this point, but the technology presents many opportunities. We will soon see if there is "independent verification" of the technology from other companies. If not, you will truly be the smartest guy in the room.
    Aug 13 05:23 PM | Likes Like |Link to Comment
  • Great News For MannKind The Company; Underwhelming News For MannKind Stock [View article]
    Beware of "Carpal Tunnel" QTR. You can make a worker's comp. claim for it. : )

    Regarding the comment below QTR--at least your detractors should no longer be able to call you a "yahoo."

    Somehow, I think that you enjoy often being seen as the villain and all the verbal jousting that follows.
    Aug 13 12:19 PM | Likes Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    I don't really understand that comment civil--what's wrong with the NASDAQ? It beats the heck out of MNKD being on the Pink Sheets.
    Aug 13 12:03 PM | Likes Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    I agree with you Robert. The shorts have not gone away--they love battle ground stocks and volatility. They will be around at least until/if solid revenues start coming in. Daily or weekly price forecasting is rather a WAG and fool's errand of course, but my thoughts are pretty much in line with yours for the next week or two. I think shorts are thinking up their talking points and will aggressively make a move soon. Over the next 3-6 months we could even see a bottom of $6 again, maybe even lower although $6 has been a solid support level since FDA approval. My best educated WAG (nice oxymoron there) for the end of the week now is 8.25--lower if the bears make a big raid on Friday (which they might as they tend to like to do these on low volume days like a Friday in the summer).
    Aug 13 11:58 AM | Likes Like |Link to Comment
  • Starbucks Is Now Selling Ice To Eskimos [View article]
    I love the title even if some see it as anachronistic. Clever title and article with some solid points.
    Aug 12 08:04 PM | 1 Like Like |Link to Comment
COMMENTS STATS
898 Comments
1,186 Likes